FREQUENCY AND SPECTRUM OF KRAS GENE MUTATIONS IN ADVANCED COLORECTAL CANCER. CLINICAL AND MORPHOLOGICAL CHARACTERISTICS

DOI: https://doi.org/None

O.I. Kit, Yu.A. Gevorkyan, N.V. Soldatkina, D.I. Vodolazhsky Rostov Research Oncological Institute, 14th line, 63, Rostov-on-Don, 344067, Russian Federation

Introduction. KRAS mutations play a critical role in human tumorigenesis and are the most prevalent in colorectal cancer. Because KRAS is the most frequently mutated factor downstream of the EGFR signaling pathway, it was considered to be a candidate molecular biomarker for anti-EGFR therapy. At the same time the associations between KRAS-mutation status and the clinical, morphological, and biological characteristics of CRC, are unclear. The aimof the study. Was to analyze KRAS gene mutations and their effect on clinical and morphological characteristics of advanced colorectal cancer. Methods. Data about 175 patients at stage T2–4N0–2M0–1 colorectal cancer were studied. 7 SNP-mutations in codons 12 and 13 KRAS gene were detected in tumor tissue samples with the useof Bio-Rad CFX96 thermocycler (Bio-Rad, USA). Results. According to the results, the frequency of mutations in the KRAS gene was 37,1%. There were identified some revealed characteristics of clinical presentations in dependence on mutation localization. Conclusion. Obtained information allows to predict possible biological behavior of tumor and create an opportunity of personalized approach to therapy and monitoring of patients.
Keywords: 
advanced colorectal cancer, mutations KRAS gene
Список литературы: 
  1. Davydov M.I., Aksel` E.M. Zlokachestvennye novoobrazovaniya v Rossii i stranah SNG v 2000 g. M., 2002. [Davydov M.I., Axel E.M. Malignant neoplasms in Russia and CIS countries in 2000. M., 2002 (in Russian)]
  2. Chissov V.I., Starinskiy V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2010 godu (zabolevaemost` i smertnost`). M., 2012. [Chissov V.I., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2010 (incidence and mortality). M., 2012 (in Russian)]
  3. Vladimirova L.Yu., Gevorkyan Yu.A., Abramova N.A., Soldatkina N.V. Ocenka e`ffektivnosti i toksichnosti monoklonal`nogo antitela k EGER panitumumaba pri kolorektal`nom rake. Materialy VII s``ezd onkologov i radiologov stran SNG. Astana. 2012; 189. [Vladimirova L.Yu., Gevorkyan Yu.A., Abramova N. A., Soldatkina N. V. Estimation of efficiency and toxicity of a monoclonal antibody to EGER of panitumumab in colorectal cancer. Materials of the VII Congress of CIS oncologists and radiologists. Astana. 2012; 189 (in Russian)]
  4. Kit O.I. Problema kolorektal`nogo raka v nachale HHI veka: dostizheniya i perspektivy. Rossiyskiy zhurnal Gastroe`nterologii, Gepatologii, Koloproktolgii. 2013; 3 (23): 65–71. [Kit O.I. Problem of colorectal cancer at the beginning of the XXI century: achievements and prospects. Russian journal of Gastroenterology, Hepatology, Coloproctology. 2013; 3 (23): 65–71 (in Russian)]
  5. Vladimirova L.Y., Kit O.I., Nikipelova E.A. et al. Resilts of monoclonal antibodies against EGFR-receptors application in patients with metastatic colorectal cancer. J. Clin. Oncol. 49th Annual Meeting of ASCO. 2013; 15 (31): 800S.
  6. Janakiraman M., Vakiani E., Zeng Z., et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010; 70: 5901–11.
  7. Gagarin I.M. Molekulyarnye markery e`ffektivnosti ingibitorov EGFR pri nemelkokletochnom rake legkogo i kolorektal`nom rake. Avtoref. dis. ... kand. med. nauk. M., 2011. [Gagarin I.M. Molecular markers of efficiency of EGFR inhibitors in non-small cell lung cancer and colorectal cancer. Manuscript. M., 2011 (in Russian)]
  8. Salts L.B., Clarke S., Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008; 26: 2013–9.
  9. Tol J., Koopman M., Cats A. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 2009; 360: 563–72.
  10. Belyaeva A.V. Mutacii v gene K-ras u bol`nyh kolorektal`nym rakom: e`pidemiologiya i klinicheskoe znachenie. Avtoref. dis. ... kand. med. nauk. Sankt-Peterburg, 2012. [Belyaeva A.V. Mutations in K-ras gene in patients with colorectal cancer: epidemiology and clinical value. Manuscript. St. Petersburg, 2012 (in Russian)]
  11. Vodolazhskiy D.I., Antonec A.V., Dvadnenko K.V. Svyaz` mutaciy gena KRAS s kliniko-patologicheskimi osobennostyami kolorektal`nogo raka u pacientov Yuga Rossii. Mezhdunarodnyy zhurnal e`ksperimental`nogo obrazovaniya. 2014; 1: 65–8. [Vodolazhsky D.I., Antonets A.V., Dvadnenko K.V. Association of KRAS gene mutations with clinical and pathological features of colorectal cancer in patients of the South of Russia. International journal of experimental education. 2014; 1: 65–8 (in Russian)]